ADCC & CDC assays

Endpoint-Based, and Speedy

Dramatic improvement of ADCC by using recombinant NK cells

Antibody therapy has been proven to be highly powerful for cancer treatment. Two important mechanisms used by antibody drugs to kill targeted tumor cells are Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), and Complement Dependent Cytotoxicity (CDC). ProBio is pleased to present to customers both a PBMC-based ADCC assay and natural kill cell-based ADCC assay. The readout is endpoint-driven (target cell lysis). The CDC assay uses normal human serum as the source of complement. By implementing strict QC standards, ProBio can provide the assurance of the efficacy and potency profiles of the therapeutic antibodies.

ADCC mechanism

ADCC Case Study

Figure 1 Concentration-dependent study of Herceptin-mediated ADCC on SK-BR-3 cells by using PBMC as effector cells (human IgG as negative control)

Figure 2 Concentration-dependent study of Erbitux-mediated ADCC on A431 cells by using freshly isolated NK cells as effector cells (Rituxan as negative control)

Figure 3 Concentration-dependent study of Humira-mediated ADCC on CHO/tm TNF-α cells by using PBMC as effector cells (human IgG as negative control). CHO/tm TNF-α was a cell line stably expressed membrane bound TNF-α at which the proteolytic cleavage site was modified.

CDC Mechanism

Case Study 1: Rituxan elicited CDC lysis of two CD20-positive leukemia cell lines

 

NHS: normal human serum

Key features of ProBio’s ADCC & CDC assay services

• Data readout is driven by the target cell lysis endpoint
• High throughput assay service for bulk antibody drug screening
• Large panel of target tumor cell lines free of charge to be used in ADCC assays
• Ready-to-go ADCC assay format for at least 4 targets, HER2/ErbB2, CD20, EGFR, and TNFα
• Ready-to-go CDC assay format for at least 2 targets, CD20 and TNFα

Media Contact
Company Name: ProBio CDMO
Email: Send Email
Phone: 1-877-436-7274 (Toll-Free)
Country: United States
Website: https://www.probiocdmo.com